Table: Astellas -2024/25 group results (IFRS)

Astellas Pharma

25/04/2025 07:30

Apr 25 (Reuters)- 
              Astellas Pharma Inc. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   Year ended      Year ended       Year to        NEXT  
                Mar 31, 2025    Mar 31, 2024   Mar 31, 2026      YEAR    
                   LATEST         YEAR-AGO        COMPANY      COMPANY   
                   RESULTS         RESULT        FORECAST    H1 FORECAST 
  Sales           1.91 trln       1.60 trln      1.93 trln               
                 (+19.2 pct)     (+5.6 pct)     (+0.9 pct)               
  Operating         41.04           25.52         160.00                 
                 (+60.8 pct)     (-80.8 pct)   (+289.9 pct)              
  Pretax            31.24           24.97         150.00                 
                 (+25.1 pct)     (-81.1 pct)   (+380.2 pct)              
  Net               50.75           17.05         130.00                 
                (+197.7 pct)     (-82.7 pct)   (+156.2 pct)              
  EPS Basic       28.35 yen       9.51 yen       72.61 yen               
  EPS Diluted     28.24 yen       9.47 yen                               
  Ann Div         74.00 yen       70.00 yen      78.00 yen               
  -Q2 Div         37.00 yen       35.00 yen      39.00 yen               
  -Q4 Div         37.00 yen       35.00 yen      39.00 yen               
 
  NOTE - Astellas Pharma Inc.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4503.T